Disrupted Healthcare – 33 Deals and Investments This Week

VC Deals (19 deals, $325M)

RiverMend Health, an Atlanta-based provider of behavioral health services to those suffering from alcohol and drug dependency, has raised $60 million in new equity funding from Norwest Venture Partners

X4 Pharmaceuticals, a Cambridge, Mass.-based developer of therapeutics designed to improve immune cell trafficking and increase the ability for T-Cells to track and destroy cancer cells, has raised $37.4 million in Series A funding led byCormorant Asset Management

AltheaDx Inc., a San Diego-based personalized medicine company, has raised $30 million in Series C funding. WuXi Healthcare Ventures led the round, and was joined by Ally Bridge Group and ALMA Life Sciences

Vidyo Inc., a Hackensack, N.J.-based provider of video collaboration solutions, has raised $15 million in new VC funding. Kaiser Permanente Ventures led the round with a $10 million investment, and was joined by return backers like Menlo Ventures, Rho Ventures, Sevin Rosen Funds and QuestMark Partners. Vidyo has now raised a total of $163 million

Doctena, a Brussels-based online medical booking platform, has raised €4.5 million in new VC funding. No investors were identified

Kahr Medical, an Israeli developer of bi-functional fusion proteins that was formed by Hadasit Bio Holding (TASE: HDST), has raised $12 million of a planned $15 million Series B round. Korea Investment Partners, Mirae Asset Venture Investment and DSC Investment were joined by return backer Flerie Invest AB

ReliefBand Technologies, a Philadelphia-based maker of a wearable device for the drug-free treatment of nausea, has raised $5 million in VC funding led byPathoCapital

Edumedics, a Louisville, Ky.-based provider of healthcare management solutions for those with diabetes or other chronic conditions, has raised $4.2 million in Series A funding. Lunsford Capital led the round, and was joined by OCA Ventures and individual angels

Clover Health, a San Francisco-based health insurance startup, has raised $35 million in Series B funding led bySequoia Capital. This comes just three months after the company raised $100 million in equity and debt funding led by First Round Capital

Sophia Genetics, a Swiss “data-driven medicine” startup, has raised $15 million in Series C funding led by Omega Pharma founder Marc Coucke

Profusa Inc., a South San Francisco-based developer of internal biosensor technology for continuous monitoring of body chemistry, has raised $13.2 million in Series B funding. 3E Bioventures (China) led the round, and was joined by return backers Asset Management Ventures and Qihoo 360

Oration, a Foster City, Calif.-based developer of software for helping employers and employees save money on pharmacy costs, has raised $11.2 million in Series A funding. Backers include DFI Venture, Google Ventures, Adreessen Horowitz, Chicago Ventures, Data Collective, Work-Bench, Arsenal Ventures Partners and TIE Angels

Inthera Bioscience, a Swiss developer of small molecule therapies for solid tumors, has raised $3.7 million in new VC funding. MS Ventures led the round, and was joined by Dutch Aglaia BioMedical Ventures, Danish Novo Seeds and EVA Basel

Orig3n, a Boston-based regenerative medicine startup focused on rare and genetically inherited diseases, has raised $12.5 million in Series A funding.Hatteras Venture Partners and Syno Capital co-led the round, and were joined by DEFTA Partners and return backers Harris & Harris Group, Inc., LabCorp, MGC Venture Partners and KTB-KORUS Fund

Hallux, a Laguna Hills, Calif.-based developer of a new dosage form and route of administration for treating onychomycosis, has raised $7.1 million in Series A funding led by Deerfield Management

Navitor Pharmaceuticals Inc., a Cambridge, Mass.-based developer of medicines targeting the activation of mTORC1, has raised $33 million in Series B funding.Brace Pharma Capital (an investment arm of Brazil’s EMS) led the round, and was joined by Remeditex Ventures, Sanofi-Genzyme BioVentures and return backers Polaris Partners, Atlas Venture, Johnson & Johnson Innovation and SR One Ltd

WellDoc, a Baltimore-based maker of a diabetes management app, has raised $22 million in Series B funding. Samsung Ventures led the round, and was joined by Merck Global Health Innovation Fund, Adage Capital Management, Excel Venture Management,Alexandria Venture Investments and Hudson River Capital Partners

Whoop, a four-year-old, Boston-based company that provides performance data to professional athletes and sports teams, has raised $3 million in strategic funding from Infosys, the India-headquartered consulting and IT firm. Whoop was spun out of the Harvard Innovation Lab; it had raised $12 million back in September

MeraDoctor, an India online platform for virtual consultations between doctors and patients raised US$1 million in pre-Series A round, led by Ronnie Screwvala’s Unilazer Ventures

PE Deals (5 deals)

CapVest Partners has agreed to acquire IBA Molecular, a France-based provider of radiopharmaceutical products and supporting services used in molecular imaging, from SK Capital. No financial terms were disclosed

The Riverside Company has invested an undisclosed amount in The Marena Group, a Lawrenceville, Ga.-based manufacturer of medical-grade compression garments, shapewear and activewear

Upstream Rehabilitation Inc., a Birmingham, Ala.-based provider of outpatient rehabilitation services, has raised an undisclosed amount of equity funding fromRevelstoke Capital Partners

AEA Investors has agreed to acquire a majority stake in1-800 Contacts Inc., an Orem, Utah-based contact lenses retailer, from Thomas H. Lee Partners(which will retain a minority equity stake). No pricing terms were disclosed for the deal, which will include leveraged financing from Credit Suisse, Barclays and Goldman Sachs

Recovery Centers of America, a King of Prussia, Penn.-based addiction treatment and behavioral health company, has raised $231.5 million in equity funding from Deerfield Management Company

IPO Deals (1 deal)

Gelesis, a Boston-based developer of therapies for weight loss and glycemic control in overweight and obese patients, withdrawn registration for an IPO that was designed to raise upwards of $56 million. It had planned to trade on the Nasdaq, with Piper Jaffray, Stifel and Guggenheim Securities serving as lead underwriters. Shareholders include PureTech Ventures (28.59% pre-IPO stake), Invesco (12.4%) and Hercules Technology Ventures (6.91%)

Other Deals (8 deals)

The Carlyle Group and Hellman & Friedman are exploring exit options forPharmaceutical Product Development LLC, a Wilmington, N.C.-based contract research organization, according to Reuters. The company could be worth between $7 billion and $8 billion, with a sale process expected to begin early next year and an IPO fallback if acceptable bids do not materialize

GTCR has agreed to sell Crealta Holdings LLC, a Glendale, Wis.-based drug maker whose lead product treats chronic refractory gout, to Horizon Pharma PLC(Nasdaq: HZNP) for $510 million in cash

Sun Pharmaceutical Industries Ltd., an India-listed drug maker, has agreed to sell its U.S. manufacturing unit — based in Bryan, Ohio — to Nostrum Laboratories Inc., a Kansas City-based subsidiary of Mylan (Nasdaq: MYL). No financial terms were disclosed

Sanofi (Paris: SASY) and Germany’s Boehringer Ingelheim are in exclusive asset swap talks, in which Saniofi would essentially trade its $12.6 billion animal health unit for Boehringer’s $7.4 billion consumer health business. Boehringer also would pay around $5.17 billion in cash to Sanofi

AstraZeneca (LSE: AZN) has agreed to acquire global rights to respiratory drugRoflumilast from Japan’sTakeda Pharmaceutical (Tokyo: 4502) for $575 million

ICON PLC (Nasdaq: ICLR) has agreed to acquire PMG Research Inc., a Winston-Salem, N.C.-based provider of clinical research services, from Frontier Capital. No financial terms were disclosed

Ligand Pharmaceuticals (Nasdaq: LGND) has agreed to acquire OMT Inc., a Palo Alto, Calif.-based company antibody platform based on the genetic engineering of animals, for approximately $178 million in cash and stock. Sellers include Essex Woodlands Health Ventures

GlaxoSmithKline (LSE: GSK) has agreed to acquire the HIV assets of Bristol-Myers Squibb (NYSE: BMY) — both late-stage R&D and a portfolio of preclinical and discovery-stage research assets — for upwards of $1.46 billion (including $350m upfront)

“We wish all our readers a restful festive season and a prosperous 2016! We will be back in January with more healthcare deal and investment news.”

Sources: Term Sheet, Financial Times, StrictlyVC, TechinAsia, CrunchBase, TechCrunch, Bloomberg

The Propell Group

#healthtech #asia